About Ethypharm
Ethypharm is a Healthcare company based in Saint-cloud (France) founded in 1977, and was acquired by PAI Partners in May 2016. Therapies for pain and addiction treatment are developed. Ethypharm has raised $248.09 million across 5 funding rounds from investors including Goldman Sachs, J P Morgan and Biovail. Ethypharm has completed 2 acquisitions, including DB Ashbourne and Martindale Pharma. Its chief executive, as recorded, is Bertrand Deluard. Ethypharm offers products and services including CNS Medicines and Hospital Injectables. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Ethypharm Group.
Company details
Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.
- Headquarters Saint-cloud, France
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website ethypharm.com
- Social LinkedIn X
- Acquired by PAI Partners (May 2016)
- Legal Name Ethypharm Group
- Annual Revenue$167.87 M (USD)-4as on Dec 31, 2016
- Net Profit$23.52 M (USD)85as on Dec 31, 2016
- Total Equity Funding$248.09M (USD)
in 5 rounds
- Latest Funding Round$557.3K (USD), Grant
Dec 2023
- InvestorsGoldman Sachs
& 5 more
- Investments & AcquisitionsDB Ashbourne
& 1 more
- Acquired byPAI Partners
(May 2016)
Products & Services of Ethypharm
Ethypharm offers a comprehensive portfolio of products and services, including CNS Medicines and Hospital Injectables.
Treatments for severe pain and addiction disorders
Medications for critical care situations
Funding Insights of Ethypharm
Ethypharm has successfully raised a total of $248.09M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $557.3 thousand completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $248.09M
- Total Rounds 5
- Last Round Grant — $557,299
- First Round $65M
(Apr 2002)
- Investors Count 5
All 5 funding rounds of Ethypharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $557,299 | Grant | – | – | |
| Apr 2021 | $952,080 | Grant | – | – | |
| Sep 2015 | $331.67M | Debt – Conventional | – | – | |
| Apr 2007 | $183.09M | Series D | – | Astorg Partners | – |
| Apr 2002 | $65M | Series C | – | Biovail | – |
6 investors in total: 6 institutional.
Investors in Ethypharm
Ethypharm has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, J P Morgan and Biovail.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
Astorg is engaged in private equity investment management. | astorg.com | Paris, France | ||
Private equity investments in market-leading companies across global sectors. | paipartners.com | |||
| economie.gouv.fr | ||||
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
R&D company focused on manufacturing of drugs for multiple therapeutic areas | 1983 | biovail.com | Mississauga, Canada |
Investor details for Ethypharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ethypharm
130 people are tracked at Ethypharm (45 in leadership, 85 in team).
| Name | Role | Group |
|---|---|---|
Bertrand Deluard | CEO & President | Leadership |
Laurence Giguel | Global Portfolio And Bd&l Director | Leadership |
Neil Peters | Head Of Marketing And Digital | Leadership |
Claire Amos | Head Of Payer Business | Leadership |
Amro Kamel | Commercial Director : Sales, Marketing & BD | Middle East & North Africa | Leadership |
Isabelle Cheval | Business Development And Marketing Director CDMO | Leadership |
Joanna Eames | Head Of Business Excellence | Leadership |
Cecile Paillous | Chief Medical & Pharmaceutical Affairs Officer | Leadership |
Denis Delval | President & CEO | Leadership |
Guilhem Maraval | COO | Leadership |
Hélène Moore | General Manager, Ethypharm Digital Therapy | Leadership |
Roseline Joannesse | Chief Legal, Ethics & Compliance Officer | Leadership |
Wayne Middleton | Head Of Supply Chain | Leadership |
Claire Gregg | Head Of Quality Systems And Compliance | Leadership |
Séverine Sy-Cornu | Corporate Talent Management & Acquisition Director | Leadership |
Paul Concannon | Senior Vice President Commercial Operations,uk | Leadership |
Rafael Danner | Head Of Sales D-a-ch | Leadership |
Xavier Lasserre | Chief Commercial Operations Officer | Leadership |
Tosan Neburagho | HR Business Partner, Industrial Affairs UK | Leadership |
Pierre-David Kramer | Finance Director - Projects / Interim Management | Leadership |
110 more people are available in the full profile.
Complete people profiles for Ethypharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ethypharm
Ethypharm has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include DB Ashbourne and Martindale Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Membrane-based humidifiers for fuel cell systems are manufactured. | martindalepharma.co.uk | Wooburn Green, United Kingdom | 1787 | Jan 2017 | •••• | |
Procurement platform for generic medicines is provided by DB Ashbourne. | dbashbourne.com | United Kingdom | 2010 | Oct 2015 | •••• |
Complete acquisition details for Ethypharm
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ethypharm
6 dated milestones of Ethypharm across 46 years, from founding to its latest funding, stage changes and deals.
- Founded Ethypharm is founded.
- Funding First funding round of $65.0M.
- Acquisition Acquires DB Ashbourne.
- Exit Acquired by PAI Partners.
- Acquisition Acquires Martindale Pharma.
- Funding Latest funding round, Grant, of $557K.
Web traffic of Ethypharm
The website of Ethypharm (ethypharm.com) receives about 3.5K visits a month and ranks #6,712,435 among all websites worldwide, #6,719 in Biotechnology and Pharmaceuticals.
- Monthly visits3.5K
▲ 32.2% vs previous month
- Unique visitors1.2K
per month
- Global rank#6,712,435
among all websites
- Category rank#6,719
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.4
- Average visit8 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Ethypharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bosnalijek.com | bosnalijek.com | 100% | – | ||
| amgen.com | 100% | 495.4K | #116,434 | View details | |
aventis.com | aventis.com | 100% | – | ||
| bharatserums.com | 100% | View details | |||
wdfpharm.com | wdfpharm.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Ethypharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ethypharm
Complete news archive for Ethypharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ethypharm
Ethypharm was founded in 1977 and raised its 1st funding round 25 years after it was founded.
Ethypharm is headquartered in Saint-cloud, France.
Bertrand Deluard is the CEO of Ethypharm, as recorded in our data.
Ethypharm is a funded company, having raised a total of $248.09M across 5 funding rounds to date. The company's 1st funding round was a Series C of $65M, raised on Apr 2002.
Annual revenue of Ethypharm is $167.87M as on Dec 31, 2016.
Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.
Ethypharm offers CNS Medicines and Hospital Injectables.
Ethypharm has made 2 acquisitions, including DB Ashbourne, and Martindale Pharma.
Ethypharm has 6 investors. Key investors include Goldman Sachs, J P Morgan, Biovail, Ministry of Economy, Finance and Industrial and Digital Sovereignty, and Astorg.
Ethypharm operates through Ethypharm Group.
Yes. Ethypharm was acquired by PAI Partners in May 2016.

